BRAF and melanoma: Amaria et al. investigated the use of neoadjuvant and adjuvant dabrafenib and trametinib vs. adjuvant-only therapy in 21 patients with surgically resectable, clinical stage III and oligometastatic stage IV BRAF-mutated melanoma.